MEDI 319 |
| Interruption of receptor tyrosine kinases (RTKs) signaling pathways has become an important aspect of anti-cancer drug discovery. The multi-targeted agents SutentTM and NexavarTM demonstrate that clinical benefit with manageable side effects is possible with broad-acting kinase inhibitors. As a part of our continuing efforts to identify backup compounds of Abbott's RTK clinical candidate ABT-869, we have developed a novel series, pyrimido[4,5-b][1,4]diazepine, as inhibitors of RTKs. Structure-activity relationship studies led to N,N'-biphenyl urea analogs that potently inhibit both vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) families of kinase as exemplified by compound 1.
|
|
Poster Session
7:00 PM-9:00 PM, Wednesday, August 22, 2007 BCEC -- Exhibit Hall - B2, Poster
Division of Medicinal Chemistry |
